Rhelion Life Sciences' subsidiary Filament Health has signed a letter of intent with Darmiyan to explore using Darmiyan's FDA-authorized AI brain imaging platform, BrainSee, in clinical trials for Rhelion's psilocybin drug candidate PEX010. BrainSee predicts Alzheimer's progression risk, potentially improving patient selection and trial efficiency. This collaboration aims to reduce trial size and duration while enhancing the detection of treatment effects in early cognitive impairment. The partnership highlights the innovative use of AI and psychedelics in Alzheimer's research, with plans to further develop clinical studies.
Berkshire Hathaway has allocated 29.7% of its $356 billion investment portfolio to just two artificial intelligence stocks. This significant concentration underscores the growing confidence and interest in AI technologies as key drivers of future gro...
RIWI Corp. reported a 40.8% year-over-year revenue decline to $885,158 for Q2 2026, mainly due to non-renewal of major contracts. Despite this, revenue grew 7.9% sequentially from Q1 2026, driven by managed services audience business improvements and...
A large Solana whale reactivated after two years, purchasing 47,535 SOL tokens worth $3.6 million during a price dip to $75. This move signals strong confidence in Solana's market resilience and has helped break a major downtrend, with SOL price risi...
Ethereum surged nearly 20% over two days, briefly hitting $2,312 and adding about $47 billion to its market cap. This rally was driven by increased US Treasury liquidity, positive regulatory signals, and a reduction in ETH available on exchanges as t...
PowerBank's 6.86 MW Brooklyn community solar project in Nova Scotia has completed environmental permitting and will begin construction in Fall 2026. Funded by AI Renewable Flow-through Fund, the project costs C$14 million and is eligible for signific...
